(S)-2-(Boc-Amino) non-8-Enoic Acidum CAS 300831-21-4 Puritas >98.0% (GC) ee >99.0%

Description:

Nomen: (S)-2-(Boc-Amino) non-8-Enoic Acid

CAS: 300831-21-4

Puritas: >98.0% (GC)

ee: >99.0%

Aspectus: Brown Liquid

Intermedia Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	(S)-2-(Boc-Amino) non-8-Enoic Acid
Synonyma	(S)-2-(tert-Butoxycarbonylamino) non-8-Enoic Acid;(S)-2-(Boc-Amino)-8-Nonenoic Acidum;(2S)-2-[(2-Methylpropan-2-yl)oxycarbonylamino]non-8-Enoic Acid;(2S)-2-{[(tert-Butoxy) carbonyl]amino}non-8-Enoic Acidum
CAS Number	300831-21-4
CATTUS Number	RF-CC347
Stock Status	In Stock
Formulae hypotheticae	C14H25NO4
M. Pondus	271.35
Density	1.035±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Liquidum fuscum
Puritas / Analysis Methodus	>98.0% (GC)
ee*	>99.0%
Test Standard	Enterprise Standard
Consuetudinem	Intermedia Paritaprevir (CAS: 1216941-48-8)

Sarcina & Repono:

sarcina: Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam mos

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

(S)-2-(Boc-Amino) non-8-Enoic Acidum (CAS: 300831-21-4) adhiberi potest ut medium in synthesi Paritaprevir (CAS: 1216941-48-8) et analogorum affinium.Paritaprevir est generationis secundae NS3/4A inhibitoris protease, est componentia omnium liberorum hepatitis C virus compositionis interferon-oris hepatitis ab Enanta pharmaceuticis et AbbVie evoluta.Fixa-dosis tabulae Paritaprevir, Ombitasvir et Ritonavir in compositione cum Dasabuvir sumptae probata est ad tractationem genotypi chronici HCV 1 in USA et EU in MMXIV, et porro probatus est ad curationem genotypi 4 chronici HCV sine cirrhosi infectio ab US. FDA in MMXV.